Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topical treatments, to advancements in systemic therapies such as targeted oral peptides for psoriasis and oral JAK-1 inhibitors for prurigo nodularis, these studies showcased promising avenues for improving patient care.
American Academy of Dermatology 2024
Meeting Wrap-Up

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topical treatments, to advancements in systemic therapies such as targeted oral peptides for psoriasis and oral JAK-1 inhibitors for prurigo nodularis, these studies showcased promising avenues for improving patient care.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Understanding Disparities in AD
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
New Drugs Helping AD Catch Up to Psoriasis
Addressing the Unique Challenges of AD Patients
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?